SCHEDULE 13G/A 0001950105 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 09/30/2025 0001850119 CENTURY THERAPEUTICS, INC. 15673T100 28 N 38th Street 11th Floor Philadelphia PA 19104 Rule 13d-1(c) Bain Capital Life Sciences Opportunities III, LP DE 0 3538609 0 3538609 3538609 N 4.1 PN CENTURY THERAPEUTICS, INC. 25 North 38th Street, 11th Floor, Philadelphia, Pennsylvania 19104. This Schedule 13G is being filed by Bain Capital Life Sciences Opportunities III, LP, a Delaware limited partnership (the "Reporting Person"). Bain Capital Life Sciences Investors, LLC, a Delaware limited liability company ("BCLSI"), is the manager of Bain Capital Life Sciences III General Partner, LLC, a Delaware limited liability company ("BCLS Fund III GP"), which is the general partner of Bain Capital Life Sciences Fund III, L.P., a Delaware limited partnership ("BCLS Fund III"), which is the sole member of Bain Capital Life Sciences Opportunities III GP, LLC, a Delaware limited liability company (together with the Reporting Person, BCLSI, BCLS Fund III GP and BCLS Fund III, the "Bain Capital Life Sciences Entities"), which is the general partner of the Reporting Person. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Reporting Person. The principal business address for each of the Bain Capital Life Sciences Entities is 200 Clarendon Street, Boston, Massachusetts 02116. Each of the Bain Capital Life Sciences Entities is organized under the laws of the State of Delaware. Y As of the close of business on September 30, 2025, the Reporting Person held 3,538,609 shares of Common Stock, representing approximately 4.1% of the outstanding shares of Common Stock. The percentage of the outstanding shares of Common Stock held by the Reporting Person is based on 86,389,098 shares of Common Stock issued and outstanding as of August 1, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the Securities and Exchange Commission on August 14, 2025. See Item 4(a) hereof. 0 3,538,609 0 3,538,609 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Bain Capital Life Sciences Opportunities III, LP /s/ Ricky Sun 11/14/2025